Key Launches Expected to Drive Zimmer Biomet’s Sales
S.E.T segment performance in 3Q17
Zimmer Biomet Holdings’ (ZBH) S.E.T. (Sports, Extremities, and Trauma) segment is comprised of surgical, sports medicine, extremities, foot and ankle, and trauma products. In 3Q17, the segment registered sales of $407 million, contributing approximately 23% to the company’s total revenues. The segment’s revenues saw a YoY growth of 1.1% in the quarter. ZBH believes that the segment is a key strategic growth driver for the company. For the nine months ending September 30, 2017, ZBH’s S.E.T. segment registered growth of 3.7%, driven by a strong product portfolio and strategic initiatives and collaborations by the company. In 3Q17, difficult comparables and supply constraints were the major factors impacting the slowdown in the segment’s performance.
Interested in ZBH? Don't miss the next report.
Receive e-mail alerts for new research on ZBH
Growth expectations ahead
The company asserts strong operational performance in the quarter with solid growth from its Gel-One and Subchondroplasty treatments, Quattro Link Knotless Anchors, A.L.P.S. Total Foot System, and the IntelliCart System for fluid waste management. The company’s DVT (deep vein thrombosis) products continue to generate strong sales growth. The specialized sales team and dedicated channel remain the major segment drivers. ZBH is the leader in shoulder implants. In 2018, it expects to strengthen its market position in the segment and witness strong growth driven by its key product launches, including comprehensive augmented baseplates and the stemless shoulder.
Investors who want industry-focused exposure to ZBH can consider investing in the Vanguard Health Care ETF (VHT), which holds 0.64% of its holdings in ZBH and 2.8%, 1.9%, and 1.1% in Medtronic (MDT), Abbott Laboratories (ABT), and Stryker (SYK), respectively.
In the next part, we’ll look at the geographical performance of Zimmer Biomet Holdings in 3Q17.